Skip to main content

International Journal of Phytomedicine and Phytotherapy

Table 2 Baseline characteristics of included patients (ITT analysis)

From: Efficacy and safety of Cineole (Soledum®) in the treatment of patients with acute bronchitis: results of an open-label randomized clinical phase III study

  Cineole group Standard group overall p-value
  n = 65 n = 65 n = 130  
Male n = 25 n = 17 n = 42  
Female n = 40 n = 48 n = 88  
Age (years, range) 44,4 (20–70) 43,7 (18–69)   0,7418
Weight (kg, range) 77,2 (51–120) 73,5 (48–104)   0,2980
Height (cm, range) 170,9 (156–196) 169,3 (155–190)   0,3553
BMI (range) 26,3 (19,2-38,2) 25,6 (17,9-36,0)   0,4775
Acute bronchitis n = 31 n = 35 n = 66  
Acute tracheobronchitis n = 34 n = 28 n = 62  
Acute tracheitis n = 2 n = 2  
BSS symptoms (range)
 Cough 2,9 (2–4) 3 (2–4)   0,3270
 Sputum 1,8 (0–4) 1,5 (0–3)   0,1270
 Chest pain 1,5 (0–3) 1,7 (0–3)   0,0784
 Wheezing 1,4 (0–2) 1,4 (0–3)   0,6293
 Dyspnea 0,8 (0–2) 1,0 (0–3)   0,2491
Total BSS Score 8,4 (5–14) 8,7 (5–14)   0,2937
Cough Frequency Likert Scale Score 5 5   
Pretreatment NSAIDs 11 8 19  
Pretreatment metamizole/paracetamol 2 5 7  
  1. ITT Intention to treat, BSS Bronchitis Severity Scale, NSAID Non-steroidal anti-inflammatory drug)